Cargando…

Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma

SIMPLE SUMMARY: Immunotherapy forms an emerging and successful field in cancer therapy using checkpoint inhibitors (e.g., anti PD-L1, anti PD-1), preventing immune escape of the tumor. However, these drugs are often only effective in a subpopulation of patients. To identify such patients, various so...

Descripción completa

Detalles Bibliográficos
Autores principales: Puladi, Behrus, Ooms, Mark, Kintsler, Svetlana, Houschyar, Khosrow Siamak, Steib, Florian, Modabber, Ali, Hölzle, Frank, Knüchel-Clarke, Ruth, Braunschweig, Till
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431396/
https://www.ncbi.nlm.nih.gov/pubmed/34503218
http://dx.doi.org/10.3390/cancers13174409
_version_ 1783750926916386816
author Puladi, Behrus
Ooms, Mark
Kintsler, Svetlana
Houschyar, Khosrow Siamak
Steib, Florian
Modabber, Ali
Hölzle, Frank
Knüchel-Clarke, Ruth
Braunschweig, Till
author_facet Puladi, Behrus
Ooms, Mark
Kintsler, Svetlana
Houschyar, Khosrow Siamak
Steib, Florian
Modabber, Ali
Hölzle, Frank
Knüchel-Clarke, Ruth
Braunschweig, Till
author_sort Puladi, Behrus
collection PubMed
description SIMPLE SUMMARY: Immunotherapy forms an emerging and successful field in cancer therapy using checkpoint inhibitors (e.g., anti PD-L1, anti PD-1), preventing immune escape of the tumor. However, these drugs are often only effective in a subpopulation of patients. To identify such patients, various so-called PD-L1 scores based on PD-L1 expression by immunohistochemistry in tumor tissue had been established. However, these scores may vary between different human investigators, which could negatively influence treatment decisions. The aim of our work was to obtain reproducible and reliable PD-L1 scores using artificial intelligence. Our results show comparable performance between human-human and human-machine interactions and could provide a deeper insight into the function and limitations of automated scoring by artificial intelligence. This could serve as a basis to improve patient selection for checkpoint inhibitors in the future. ABSTRACT: Immune checkpoint inhibitors (ICI) represent a new therapeutic approach in recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). The patient selection for the PD-1/PD-L1 inhibitor therapy is based on the degree of PD-L1 expression in immunohistochemistry reflected by manually determined PD-L1 scores. However, manual scoring shows variability between different investigators and is influenced by cognitive and visual traps and could therefore negatively influence treatment decisions. Automated PD-L1 scoring could facilitate reliable and reproducible results. Our novel approach uses three neural networks sequentially applied for fully automated PD-L1 scoring of all three established PD-L1 scores: tumor proportion score (TPS), combined positive score (CPS) and tumor-infiltrating immune cell score (ICS). Our approach was validated using WSIs of HNSCC cases and compared with manual PD-L1 scoring by human investigators. The inter-rater correlation (ICC) between human and machine was very similar to the human-human correlation. The ICC was slightly higher between human-machine compared to human-human for the CPS and ICS, but a slightly lower for the TPS. Our study provides deeper insights into automated PD-L1 scoring by neural networks and its limitations. This may serve as a basis to improve ICI patient selection in the future.
format Online
Article
Text
id pubmed-8431396
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84313962021-09-11 Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma Puladi, Behrus Ooms, Mark Kintsler, Svetlana Houschyar, Khosrow Siamak Steib, Florian Modabber, Ali Hölzle, Frank Knüchel-Clarke, Ruth Braunschweig, Till Cancers (Basel) Article SIMPLE SUMMARY: Immunotherapy forms an emerging and successful field in cancer therapy using checkpoint inhibitors (e.g., anti PD-L1, anti PD-1), preventing immune escape of the tumor. However, these drugs are often only effective in a subpopulation of patients. To identify such patients, various so-called PD-L1 scores based on PD-L1 expression by immunohistochemistry in tumor tissue had been established. However, these scores may vary between different human investigators, which could negatively influence treatment decisions. The aim of our work was to obtain reproducible and reliable PD-L1 scores using artificial intelligence. Our results show comparable performance between human-human and human-machine interactions and could provide a deeper insight into the function and limitations of automated scoring by artificial intelligence. This could serve as a basis to improve patient selection for checkpoint inhibitors in the future. ABSTRACT: Immune checkpoint inhibitors (ICI) represent a new therapeutic approach in recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). The patient selection for the PD-1/PD-L1 inhibitor therapy is based on the degree of PD-L1 expression in immunohistochemistry reflected by manually determined PD-L1 scores. However, manual scoring shows variability between different investigators and is influenced by cognitive and visual traps and could therefore negatively influence treatment decisions. Automated PD-L1 scoring could facilitate reliable and reproducible results. Our novel approach uses three neural networks sequentially applied for fully automated PD-L1 scoring of all three established PD-L1 scores: tumor proportion score (TPS), combined positive score (CPS) and tumor-infiltrating immune cell score (ICS). Our approach was validated using WSIs of HNSCC cases and compared with manual PD-L1 scoring by human investigators. The inter-rater correlation (ICC) between human and machine was very similar to the human-human correlation. The ICC was slightly higher between human-machine compared to human-human for the CPS and ICS, but a slightly lower for the TPS. Our study provides deeper insights into automated PD-L1 scoring by neural networks and its limitations. This may serve as a basis to improve ICI patient selection in the future. MDPI 2021-08-31 /pmc/articles/PMC8431396/ /pubmed/34503218 http://dx.doi.org/10.3390/cancers13174409 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Puladi, Behrus
Ooms, Mark
Kintsler, Svetlana
Houschyar, Khosrow Siamak
Steib, Florian
Modabber, Ali
Hölzle, Frank
Knüchel-Clarke, Ruth
Braunschweig, Till
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
title Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
title_full Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
title_fullStr Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
title_full_unstemmed Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
title_short Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
title_sort automated pd-l1 scoring using artificial intelligence in head and neck squamous cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431396/
https://www.ncbi.nlm.nih.gov/pubmed/34503218
http://dx.doi.org/10.3390/cancers13174409
work_keys_str_mv AT puladibehrus automatedpdl1scoringusingartificialintelligenceinheadandnecksquamouscellcarcinoma
AT oomsmark automatedpdl1scoringusingartificialintelligenceinheadandnecksquamouscellcarcinoma
AT kintslersvetlana automatedpdl1scoringusingartificialintelligenceinheadandnecksquamouscellcarcinoma
AT houschyarkhosrowsiamak automatedpdl1scoringusingartificialintelligenceinheadandnecksquamouscellcarcinoma
AT steibflorian automatedpdl1scoringusingartificialintelligenceinheadandnecksquamouscellcarcinoma
AT modabberali automatedpdl1scoringusingartificialintelligenceinheadandnecksquamouscellcarcinoma
AT holzlefrank automatedpdl1scoringusingartificialintelligenceinheadandnecksquamouscellcarcinoma
AT knuchelclarkeruth automatedpdl1scoringusingartificialintelligenceinheadandnecksquamouscellcarcinoma
AT braunschweigtill automatedpdl1scoringusingartificialintelligenceinheadandnecksquamouscellcarcinoma